RZ 358

Drug Profile

RZ 358

Alternative Names: RZ358; X 358; XOMA 247; XOMA 358; XPA.15.247

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperinsulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperinsulinaemia; Hypoglycaemia

Most Recent Events

  • 07 Dec 2017 RZ 358 licensed to Rezolute worldwide for the treatment of Hyperinsulinaemia (Congenital)
  • 26 Apr 2017 XOMA plans a phase IIb trial for Congenital hyperinsulinism (children) in United Kingdom in 2018
  • 01 Apr 2017 Updated efficacy data from a phase II trial in Hyperinsulinaemia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top